Skip to content

Altimmune ALT Free cash flow

Free cash flow at other companies

Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Merck & Co. logo
Merck & Co.MRK
$2.93B+150%
Wave Life Sciences logo
Wave Life SciencesWVE
-$59.99M+5.1%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$15.8M+141%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$229.43M-11,360%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL

Other financials

Income statement

See full
Revenue$26.0K+420%
Operating income-$24.2M-11.1%
Net income-$22.6M-15.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$97.6M+98.7%
Total debt$34.8M+14,092%
Total equity$284.0M+99.8%
Total assets$335.6M+113%

Cash flow

See full
Operating cash flow-$20.9M-24.4%
CapEx$21.0K

Valuation

See full
Market cap$558.14M-2.1%
Enterprise value$495.27M-5.0%
P/S13,613.2×-24,380×

Profitability

See full
Operating margin-230,461%-82,087pp
Net margin-214,861%-76,057pp
FCF margin-17,806.8%-110,030pp

Returns & leverage

See full
Return on equity-42.7%-8.7pp
Debt / equity0.1×+0.1×
Current ratio29.6×+13.7×

Where this comes from

Calculated from Altimmune’s reported figures.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Altimmune's free cash flow?
Altimmune (ALT) reported free cash flow of -$20.96M in Q1 2026.
What is the long-term trend for Altimmune's free cash flow?
Over 2 years (2021 to 2023), Altimmune's free cash flow has grown at a -8.4% compound annual growth rate (CAGR), from -$90.36M to -$75.86M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.